STADA Arzneimittel AG: Generics with “value for money”

Description: STADA: Generics with “value for money” Generics contributed 74.8% to sales in 2004 (previous year: 73.7%) and represents STADA’s largest core segment by far.

Keywords: generics, generic, largest core segment, expiration of the patent, commercial property rights, lower prices, initial supplier, same active ingredient, multisource products, active ingredients, strong growth potential, low-cost therapy, effective, public health care systems, price, costs, national market risks, ALIUD PHARMA, Omeprazole, Simvastatin, Mirtazapine, Enalapril, Penicillin, sales companies, internationalization, know-how

Tags: biogenrx, stada, generics, money, value, arzneimittel, active, group, products, generic, suchen, lupe, weiter, ingrediments, zurück, sales, website, press, market, home, english, segment, year, core, previous, largest, prices, share, financial, growth, contributed, reports, releases, far, represents, hoc, russia, german, photos, profile,

Biogenrx.net

Content Revalency: Title: 62.50%   Description: 60.00%   Keywords: 60.00%  |  Document size: 31,643 bytes
More info: Whois - Trace Route - RBL Check